Paul M. Kinsella

Partner

kinsella-paul-m
  • JD, with distinction, Stanford Law School, 1993
  • BA, summa cum laude, Boston College, 1988

Qualifications

  • Massachusetts, 1995
  • California, 1993
  • North Carolina, 2017
  • IFLR1000, Rising Star (2019)
  • The Legal 500 (2014-2018)
  • Chambers USA: America's Leading Lawyers for Business (2011-2019)
  • The Best Lawyers in America (2006-2012, 2015-2019)
  • Massachusetts Super Lawyers (2014-2016)

Paul M. Kinsella

Partner

Paul advises on business combinations, securities offerings, and governance matters.

Experience

Matters include representation of:

  • TESARO in its sale to GSK ($5.1 billion)
  • NxStage in its sale to Fresenius ($2.0 billion)
  • The lead underwriters in the Elanco Animal Health IPO ($1.7 billion) and the dealer managers in the exchange of Elanco stock for Lilly stock ($8.6 billion)
  • Ironwood in IPO; securities and governance matters; and spin-off of Cyclerion
  • Pfizer in its acquisitions of Medivation ($14 billion) and Hospira ($17 billion) and securities law matters
  • Shire in acquisitions of Baxalta ($32 billion) and Dyax ($5.9 billion)
  • Wright Medical in merger with Tornier ($3.3 billion) and securities and governance matters
  • Cubist in sale to Merck ($9.5 billion); acquisitions of Trius, Optimer, and Adolor; and securities and governance matters
  • Genzyme in sale to Sanofi ($20.1 billion); acquisitions of Bioenvision, AnorMED, Bone Care, ILEX ($1.1 billion), SangSat, Focal, GelTex ($1.3 billion) and Biomatrix; and securities and governance matters

Publications

Cookie Settings